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Captopril, an inhibitor of angiotensin converting enzyme (ACE), is
used to treat medical conditions like hypertension and heart
failure, and it is usually administered in tablet form for adults.
Since this dosage form is not recommended for infants and
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children up to 6 years, hospital pharmacies have to prepare liquid
formulations for oral administration of captopril. Traditionally,
concentration of captopril used in the formulations is 1mg/ml.
The problem is that captopril is prone to oxidation, and its stability
in solution is affected by pH, concentration of captopril, the
presence of oxygen or metal ions.
The influence of different formulation ingredients on the
properties of physical and chemical stability of captopril in liquid
preparations has been evaluated.
Discussion: Why is this important?
1. Formulation B is more conservative than formulation A at all tested 
storage conditions (less degradation of captopril occurs after a 30 days 
period)
2. Best performance of formulation B when stored at room temperature 
• To evaluate the stability of captopril for 30 days when formulated 
in a 1 mg/ml suspension adjuvanted with citric acid. 
Goals
Figure 1 - Equation of the degradation of captopril in the captopril disulfide
Table 1 - Stability of captopril 1mg/ml suspensions: percentage of initial concentrationa remaining (Mean ± SD)
Time
Formulation-storage conditions
A-i. A-ii. A-iii. B-i. B-ii. B-iii.
Day 0 100,0% ±0,024 100,0% ±0,024 100,0% ±0,024 100,0% ±0,024 100,0% ±0,024 100,0% ±0,024
6 days 77,9% ±0,007 76,1% ±0,001 83,5% ±0,002 86,3% ±0,000 78,0% ±0,006 86,0% ±0,003
9 days 79,7% ±0,010 74,6% ±0,002 81,4% ±0,003 91,5% ±0,003 81,5% ±0,001 84,9% ±0,001
13 days 76,8% ±0,004 70,9% ±0,002 82,3% ±0,029 92,6% ±0,003 82,0% ±0,005 86,9% ±0,006
16 days 73,2% ±0,001 71,6% ±0,001 79,2% ±0,002 90,1% ±0,002 80,1% ±ND 84,2% ±0,006
20 days 73,4% ±0,001 69,2% ±0,001 75,0% ±0,006 93,1% ±0,001 80,8% ±ND 84,7% ±0,001
23 days 72,9% ±0,001 69,2% ±0,002 74,8% ±0,004 92,9% ±0,007 82,3% ±0,001 84,6% ±0,002
27 days 70,1% ±ND 68,0% ±0,004 75,6% ±0,001 92,3% ±0,001 77,9% ±ND 87,2% ±0,005
30 days 73,8% ±ND 68,6% ±0,004 76,9% ±0,001 92,9% ±0,013 81,6% ±0,001 86,1% ±0,001
Key: a initial concentration = 1.486 (±0,024); SD = standard deviation (n= 3, lower and upper 95% confidence limits); ND = not 
determined
Figure 2 – HPLC chromatogram obtained after 30 days of captopril suspension storage at room temperature, protected 
from light. 3.a) – Formulation A; 3.b) – Formulation B. A – captopril; B – captopril disulphide; C citric acid.
Materials and Methods and protected from light (92.93% of the initial concentration remaining 
at day 30)
3. pH remains stable below 4 during 30 days for both formulations 
(results not shown)
4. Exposure to light is the condition that further compromises captopril 
stability
The results obtained from this project demonstrate that, as long as  
the suspension is properly packed in brown glass flasks and stored 
at room temperature protected from direct light incidence:
• Citric acid is able to maintain captopril stability in  1mg/ml 
extemporaneous oral suspensions for 30 days without 
changing pH;
• When refrigeration is not available, citric acid conserves 
captopril  in 1mg/ml suspensions better than a non 
adjuvanted suspension.
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Captopril suspensions of 1 mg/ml were prepared from 25 mg 
tablets in purified water
Formulation A: 
1mg/ml captopril
Suspensions were placed in amber glass bottles of 100 ml, pH was 
monitored, and stored under different environmental conditions 
i. Room temperature 
(22±2ºC) 
ii. Direct sunlight 
Captopril chemical stability (retention of at least 90% of the initial concentration of 
captopril in the formulation) of was evaluated by determination by high performance 
liquid chromatography (HPLC) on days 0, 6, 9, 13, 16, 20, 23, 27 and 30 of storage.
iii. Refrigeration 
(5±3ºC)
Formulation B: 1mg/ml captopril 
+ 0,03% citric acid
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